Astrazeneca Pharma India Share Price Hits Fresh 52-Week Low at Rs 6,594: Key Reasons Behind the Fall
- September 24, 2026
- Posted by: Harsh Piplani
- Category: News
Astrazeneca Pharma India Share Price fell to Rs 6,594, down 1.72% from the previous close, and matched its fresh 52-week low as the company’s market capitalisation stood at Rs 16,773 crore. Astrazeneca Pharma India Ltd. (ASTRAZEN) is now in focus for Astrazeneca Pharma India Share Price Today, Astrazeneca Pharma India Stock News and Astrazeneca Pharma India Share Price News as the session confirmed a new yearly low in the Indian stock market. The supplied data confirms the price event, while the event itself is relevant because the current price, day range and market cap are all visible in one move. Univest tracks this kind of stock news in a clean, fact-first format.
The move also keeps Astrazeneca Pharma India Share Price on the radar for readers searching Astrazeneca Pharma India Share Price Live, Astrazeneca Pharma India Share News and Astrazeneca Pharma India Latest News. In this article, Univest breaks down the price action, valuation context, sector comparison and peer positioning using only the figures provided.
Astrazeneca Pharma India Share Price Today: Price Action Analysis
| Metric | Value |
|---|---|
| Current Price | Rs 6,594 |
| Previous Close | Rs 6,709.2 |
| Today's Move | Rs -115.2 (-1.72%) |
| Open | Rs 6,678.8 |
| High | Rs 6,701 |
| Low | Rs 6,594 |
| Turnover | Rs 0.17 crore |
| Market Capitalisation | Rs 16,773 crore |
Astrazeneca Pharma India Ltd. (ASTRAZEN) traded at Rs 6,594. versus the previous close of Rs 6,709.2, a fall of 1.72%. The stock opened at Rs 6,678.8, reached Rs 6,701, touched Rs 6,594.
Astrazeneca Pharma India Share Price Today closed at Rs 6,594 after opening at Rs 6,678.8, touching an intraday high of Rs 6,701 and a low of Rs 6,594. The stock finished Rs 115.2 lower than the previous close of Rs 6,709.2, which is a decline of 1.72%. Because the day low and the 52-week low are both Rs 6,594, the session ended at a fresh 52-week low and a fresh one-year low.
Turnover for the session stood at Rs 0.17 crore, while market capitalisation remained Rs 16,773 crore. On the verified numbers alone, the day was defined by a weak close relative to the previous session and a range that compressed into the low of the day. For readers following Astrazeneca Pharma India Share Price Update, the key point is simple: the stock is now at its yearly low and sits below the prior close, which makes the event newsworthy in Astrazeneca Pharma India Stock News and Astrazeneca Pharma India Share Price Today coverage.
That factual price action sets up the broader question of whether the company’s valuation, earnings quality and sector context justify renewed attention in Astrazeneca Pharma India Stock Analysis and Astrazeneca Pharma India Share Price News.
Astrazeneca Pharma India Ltd. (ASTRAZEN) Fundamental Analysis
| Metric | Value |
|---|---|
| Market Capitalisation | Rs 16,773 crore |
| P/E Ratio | 98.89x |
| P/B Ratio | 18.55x |
| ROE | 23.02% |
| ROCE | 31.24% |
| EPS | Rs 67.85 |
| Book Value Per Share | Rs 361.68 |
| Dividend Yield | 0.54% |
Astrazeneca Pharma India Ltd. (ASTRAZEN) fundamental metrics show P/E 98.89x, P/B 18.55x, ROE 23.02%, ROCE 31.24%. These figures provide context only and are not a buy or sell signal.
Astrazeneca Pharma India Ltd. has a market capitalisation of Rs 16773 crore, which gives readers a sense of company size before judging valuation. On valuation, P/E at 98.89x, P/B at 18.55x should be read against the sector and peer benchmarks rather than as a standalone signal. Profitability is represented by ROE of 23.02% and ROCE of 31.24%, helping investors compare shareholder returns and capital efficiency. Additional supplied metrics include EPS of Rs 67.85, book value per share of Rs 361.68, dividend yield of 0.54%, adding context to earnings, balance-sheet value and historical payout. Against the supplied same industry benchmark, these figures can be compared with benchmark median P/E of 31.89x, median ROE of 11.69%, median ROCE of 13.32%. These numbers explain the fundamental backdrop without converting the article into a buy or sell view.
Sector and Industry Context
| Metric | Value |
|---|---|
| Sector | Healthcare |
| Industry | Pharmaceuticals & Drugs |
| Benchmark Scope | same industry |
| Company P/E Ratio | 98.89x |
| Benchmark Median P/E | 31.89x |
| Benchmark Average P/E | 49.72x |
| Benchmark P/E Range | 3.48x to 762.66x |
| Company P/B Ratio | 18.55x |
| Benchmark Median P/B | 2.95x |
| Company ROE | 23.02% |
| Benchmark Median ROE | 11.69% |
| Company ROCE | 31.24% |
| Benchmark Median ROCE | 13.32% |
| Company Market Capitalisation | Rs 16,773 crore |
| Benchmark Median Market Cap | Rs 745.38 crore |
Astrazeneca Pharma India Ltd. (ASTRAZEN) is classified under sector: Healthcare and industry: Pharmaceuticals & Drugs.
Astrazeneca Pharma India Ltd. (ASTRAZEN) has a P/E ratio of 98.89x, which is above the benchmark median of 31.89x, a difference of +210.1%. P/E is a valuation multiple and is not, by itself, a buy or sell signal.
Astrazeneca Pharma India Ltd. (ASTRAZEN) has a ROE of 23.02%, which is above the benchmark median of 11.69%, a difference of +96.92%. Astrazeneca Pharma India Ltd. (ASTRAZEN) has a ROCE of 31.24%, which is above the benchmark median of 13.32%, a difference of +134.53%.
Track stocks falling to yearly lows through the Univest 52-week-low screener. The peer table below provides the company-level comparison.
Peer Comparison
| Company | Symbol | Market Cap (Cr) | P/E | P/B | ROE (%) | ROCE (%) |
|---|---|---|---|---|---|---|
| Glenmark Life Sciences Ltd. | ALIVUS | 16,982.36 | 28.16 | 4.87 | 18.41 | 24.61 |
| Alembic Pharmaceuticals Ltd. | APLLTD | 16,518.18 | 23.93 | 2.84 | 12.35 | 11.74 |
| Jubilant Pharmova Ltd. | JUBLPHARMA | 17,055.82 | 47.89 | 2.36 | 5.97 | 8.69 |
| Suven Pharmaceuticals Ltd. | COHANCE | 17,308.7 | 166.23 | 4.59 | 4.02 | 6.12 |
| Concord Biotech Ltd. | CONCORDBIO | 16,013.08 | 59.23 | 7.87 | 13.54 | 18.04 |
Astrazeneca Pharma India Ltd. (ASTRAZEN) has a P/E ratio of 98.89x compared with the displayed peer median of 47.89x. This is a relative valuation comparison, not a buy or sell signal. Its ROE of 23.02% compares with a peer median of 12.35% across the companies shown in the table. ROCE stood at 31.24% versus the displayed peer median of 11.74%, providing a capital-efficiency comparison. Astrazeneca Pharma India Ltd. (ASTRAZEN) has a market capitalisation of Rs 16,773 crore. Among the 5 peers shown, 3 have a larger market capitalisation.
Why Investors Are Watching Astrazeneca Pharma India
- Astrazeneca Pharma India Share Price hit Rs 6,594, which is also the fresh 52-week low and one-year low for the session.
- The stock closed 1.72% lower than the previous close of Rs 6,709.2 after opening at Rs 6,678.8.
- Market capitalisation stood at Rs 16,773 crore, placing Astrazeneca Pharma India Share Price within the supplied peer-cap range.
- P/E of 98.89 and P/B of 18.55 sit above the sector medians of 31.89 and 2.95 in the same-industry benchmark.
- ROE of 23.02%, ROCE of 31.24%, EPS of Rs 67.85 and book value of Rs 361.68 per share add context to Astrazeneca Pharma India Fundamental Analysis.
About Astrazeneca Pharma India
Astrazeneca Pharma India Ltd. operates in the Healthcare sector and the Pharmaceuticals & Drugs industry. The supplied data places the company within a 199-company same-industry benchmark and a 286-company same-sector benchmark. Its listed profile is tracked on NSE and BSE, and Astrazeneca Pharma India Share Price is followed by investors alongside company financials, market capitalisation, valuation ratios and sector context.
For Astrazeneca Pharma India Stock News and Astrazeneca Pharma India Company News readers, the core factual profile remains the same: the company is part of a large healthcare comparison set, its share price has reached a fresh yearly low, and its supplied financial ratios remain central to any Astrazeneca Pharma India Stock Analysis.
Track Astrazeneca Pharma India Share Price on Univest
Use Astrazeneca Pharma India Ltd. (ASTRAZEN) live share-price page, Univest 52-week-low screener, Univest market blogs to review live stock data, yearly-low lists and related market analysis.
Track Astrazeneca Pharma India Share Price on Univest for live share price, stock news, fundamental ratios, shareholding pattern, 52-week levels and market insights. Univest presents Astrazeneca Pharma India Share Price Today alongside company-specific data, peer comparisons and sector context in one place.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Frequently Asked Questions
Why did Astrazeneca Pharma India Share Price hit a fresh 52-week low?
Ans. The supplied data confirms that Astrazeneca Pharma India Share Price fell 1.72% to Rs 6,594, which matched the day low and the fresh 52-week low. The data confirms the price event, but not a company-specific catalyst.
What is Astrazeneca Pharma India Share Price today?
Ans. Astrazeneca Pharma India Share Price today is Rs 6,594. It closed below the previous close of Rs 6,709.2 after opening at Rs 6,678.8, and the session ended at the fresh yearly low.
How much did Astrazeneca Pharma India stock fall today?
Ans. Astrazeneca Pharma India stock fell Rs 115.2 or 1.72% from the previous close. The movement also carried the stock to Rs 6,594, which is the same as its 52-week low for the day.
What is the market capitalisation of Astrazeneca Pharma India?
Ans. Astrazeneca Pharma India has a market capitalisation of Rs 16,773 crore. That places the company well above the industry median in the supplied benchmark set and close to the peer cluster shown.
Is Astrazeneca Pharma India expensive on valuation?
Ans. On the supplied numbers, Astrazeneca Pharma India trades at a P/E of 98.89 and a P/B of 18.55. Both are above the sector medians of 31.89 and 2.95, which keeps valuation elevated versus the benchmark.
How do Astrazeneca Pharma India ROE and ROCE compare with the sector?
Ans. Astrazeneca Pharma India reports ROE of 23.02% and ROCE of 31.24%. Both are higher than the sector medians of 11.69% and 13.32% in the same-industry benchmark supplied with the data.
What do EPS and book value show for Astrazeneca Pharma India Share Price?
Ans. EPS is Rs 67.85 and book value is Rs 361.68 per share. EPS reflects earnings attributable to each share, while book value shows accounting net worth per share behind Astrazeneca Pharma India Share Price.
Which sector and industry does Astrazeneca Pharma India belong to?
Ans. Astrazeneca Pharma India belongs to the Healthcare sector and the Pharmaceuticals & Drugs industry. The supplied benchmark covers 199 same-industry companies and 286 same-sector companies for comparison. The stock belongs to the Healthcare sector.
How does Astrazeneca Pharma India compare with peers on returns?
Ans. In the supplied peer set, Astrazeneca Pharma India’s ROE of 23.02% and ROCE of 31.24% are higher than each peer shown. That gives the stock a stronger return profile on the displayed figures.
Where can I track Astrazeneca Pharma India Share Price news?
Ans. Univest tracks Astrazeneca Pharma India Share Price news, live price levels, company ratios, sector benchmarks and peer comparison in one place. The stock-detail page also helps readers follow the 52-week low event.
